Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc. (NYSE: PFE), to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity™ smart liquid biopsy platform.

1. Global IVD Market According to IQVIA statistics, the global IVD market expanded 6% LC in 2023, continuing to show a rebound from the COVID period. In 2023, the global IVD market size reached USD 81 bi..

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 29, 2025.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the introduction of its innovative Chest Pain Triage algorithm as part of the navifyⓇ Algorithm Suite. This groundbreaking algorithm is designed to more quickly and accurately detect Acute Coronary Syndrome (ACS) in patients presenting with chest pain, one of the most common reasons for Emergency Department (ED) visits. As EDs are typically one of the most crowded hospital units, leading to challenges to swiftly diagnose critical conditions, such as chest pain. This new algorithm was developed in collaboration with Universitätsklinikum Heidelberg.

Original from: Quest Diagnostics · First quarter revenues of $2.65 billion, up 12.1% from 2024 · First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjust..

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 28, 2025.

China's healthcare sector is making steady progress in opening up to foreign investment and expertise, with more than 150 joint-venture and wholly overseas-invested medical institutions now operating nationwide, a senior health official announced Monday.

Autobio On April 17, Autobio released its 2024 annual report. The company's operating revenue was RMB 4.471 billion, a slight increase of 0.62% year-on-year. Net profit attributable to shareholders fell 1.89% to..

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will invest USD 50 billion into the United States of America in the next five years. These investments further strengthen Roche’s already significant US footprint with 13 manufacturing and 15 R&D sites across the Pharmaceutical and Diagnostics Divisions, and are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and North Mississippi Health Services announced today that Labcorp has completed its acquisition of North Mississippi Health Services’ ambulatory outreach laboratory business and become a referral laboratory for its seven hospitals and clinic laboratories.

The Trump administration's fiscal-year 2026 budget proposal calls for a roughly 40 percent cut in funding for the National Institutes of Health.

Diasorin (FTSE MIB: DIA) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the second1 of its 3 multiplex molecular panels for blood culture pathogen identification on the LIAISON PLEX® system.

Chinese President Xi Jinping said here Thursday that building a China-Cambodia community with a shared future is a choice of history and the people.

BioMérieux's year-over-year sales grew approximately 14 percent for the first quarter, the firm reported on Thursday, prompting it to confirm its previous full-year revenue guidance.

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution. KEYTRUDA is an anti-PD-1 therapy developed by Merck (known as MSD outside the United States and Canada).

China and Malaysia have agreed to build a high-level strategic China-Malaysia community with a shared future to accelerate their modernization efforts and jointly promote regional and global prosperity and stability.

GeneDx said Wednesday that it plans to acquire Fabric Genomics for $33 million in cash with the potential consideration rising to $51 million if certain milestones are met.

SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has been approved by Health Canada. This approval marks an important milestone in addressing a significant global unmet need in axSpA.

Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients.

nSAGE, Caszyme, and Vilnius University have joined forces to form a consortium which will develop a new, advanced diagnostics solution. The UNCOVER project will develop a universal, CRISPR-based diagnostics platform for accurate and rapid detection of infectious diseases. This platform will be versatile, user-friendly, applicable to both human and animal health, and will be easily programable to address a wide range of pathogens and disease biomarkers.